Prolia is a prescription medication used primarily to treat osteoporosis in postmenopausal women and men at high risk of fractures, individuals who have failed or are intolerant to other available osteoporosis therapy. Its active ingredient, denosumab, is a monoclonal antibody that works by inhibiting the activity of osteoclasts, the cells responsible for bone resorption. By doing so, Prolia helps to increase bone mass and strength, significantly reducing the risk of spinal, non-spinal, and hip fractures. Administered via subcutaneous injection every six months, Prolia is a powerful option for those looking to manage their osteoporosis and maintain bone health. However, it is important for patients to be aware of potential side effects, including the risk of serious infections, and to discuss these with their healthcare provider.